Merit Medical’s PhD Polycarbonate Hemostasis Valve Launched in the United States

 

May 30, 2019—Merit Medical Systems, Inc. announced the United States launch of its PhD ("Push, Hold, Deliver”) polycarbonate hemostasis control valve. The PhD device has been available to European markets since 2014.

According to the company, the dual-seal PhD device allows operators to manipulate the valve with one hand by pressing down on the cap, keeping the other hand free for the insertion and withdrawal of diagnostic/interventional devices. The device's two seals—a primary compression seal and a secondary polyisoprene push-and-release bleedback seal—help minimize blood loss without restricting device movement. The PhD device allows for pressure injections up to 400 psi, accommodates devices up to 7.3 F, and features a clear body that provides unobstructed visibility.

In the United States, Merit will offer the device as a stand-alone product or in combination with Merit’s suite of leading inflation devices and custom kits. Merit will also offer optional sidearm extension tubing that creates additional space between the valve and connected devices.

The commercial launch of the PhD device comes after the late-2018 introduction of Merit’s basixTau inflation device, which features a foldout handle that can increase the speed of inflations and deflations. The basixTau inflation device provides versatility and ease of use, while reducing rotational force by up to 67%. It is also designed with a clear barrel for visibility and an easy-to-read luminescent analog display suitable for use in low-light procedures. The 20-mL device can achieve a maximum pressure of 30 atm, advised the company.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.